Hepatitis Treatment News : FDA Gives Hep C Drug Simeprevir Priority Review

A Smart + Strong Site
Subscribe to:
Hepatitis E-newsletter
Join Us:

Back to home » Hepatitis Treatment News » May 2013


emailprint

May 20, 2013

FDA Gives Hep C Drug Simeprevir Priority Review

The U.S. Food and Drug Administration (FDA) has given Janssen Research & Development priority review status for its investigational hepatitis C therapy simeprevir. Janssen submitted its New Drug Application (NDA) in the end of March for approval of the NS3/4A protease inhibitor for use with pegylated interferon and ribavirin among those with genotype 1 of hep C who have compensated liver disease.

The FDA grants priority review to drugs that may offer a major advance in treating a condition. Currently, there are two protease inhibitors approved to treat hep C, Incivek (telaprevir) and Victrelis (boceprevir). By law, the FDA review will begin about 60 days after the NDA with a goal of completing the process within six months. Thus, the review will start at the end of May and should be completed by the end of November.

Janssen submitted its NDA for simeprevir based in part upon results from three Phase III studies: QUEST-1 and QUEST-2, which studied the drug in treatment-naive people with hep C, and PROMISE, which gave simeprevir to those who had relapsed after a previous interferon-based treatment for the virus.

To read the Janssen release, click here.

To read the Fox Business story, click here.

Search: Hepatitis C virus, HCV, hep C, simeprevir, U.S. Food and Drug Administration, FDA, Janssen Research & Development, priority review, Incivek, telaprevir, Victrelis, boceprevir, new drug application, NDA, QUEST-1, QUEST-2, PROMISE.


Scroll down to comment on this story. Click here to visit the Hep Forums and ask questions about this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The Hep team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (1 total)


[Go to top]

Quick Links
Current Issue
Forums
Poll
Blogs
Hep TV
Calendar
Services Directory
Conference News
Top Stories
Treatment News
Hep Exclusives
All About Hepatitis
• Hepatitis A
Transmission
Prevention
Treatment
• Hepatitis B
Transmission
Prevention
Treatment
• Hepatitis C
Transmission
Prevention
Treatment
HCV/HIV Coinfection
Help Paying For Meds
Clinical Trials
TALK TO US
Tell us what you think
Poll
Would you consider using medical marijuana to help ease side-effects of hepatitis C treatment?
Yes
No
Not sure


Survey
USA Today/Hepatitis C Awareness Survey

Hepatitis C Reader Survey
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.